20 Stocks Insiders Bought in April After Trump’s Tariff Rollout

18. XOMA Royalty Corporation (NASDAQ:XOMA)

XOMA Royalty is a biotech royalty aggregator focused on early to mid-stage clinical assets and late-stage commercial ones. It holds economic rights to milestone and royalty payments from partnered therapeutic candidates. The company, headquartered in Emeryville, California, was formerly known as XOMA Corporation and changed its name in July 2024.

This month, one insider acquired approximately $760,145 worth of XOMA Royalty shares at an average price of $25.41 per share. Year-to-date, the stock is down 26.05%, trading at $19.43 per share. Over the past 12 months, the stock lost 23.00%.

XOMA Royalty reported total income and revenues of $8.7 million and $28.5 million for the fourth quarter and full year of 2024, respectively. In 2023, XOMA Royalty recorded total income and revenues of $1.8 million and $4.8 million for the fourth quarter and full year, respectively.  The increase for the full year of 2024 was primarily driven by an increase in the company’s income from purchased receivables.

Based on three Wall Street analysts’ estimates, XOMA Royalty stock is a “Moderate Buy” with a price target of $79.50 per share, according to TipRanks. The average price target suggests a 299.50% upside from the latest price.